Literature DB >> 28161296

Successful treatment of Talaromyces amestolkiae pulmonary infection with voriconazole in an acute lymphoblastic leukemia patient.

Hiram Villanueva-Lozano1, Rogelio de J Treviño-Rangel2, Erick W Renpenning-Carrasco3, Gloria M González4.   

Abstract

Infections due to Talaromyces spp. are uncommon, but they have been reported previously as causative agents of disease in immunocompromised patients. The prognosis of hemato-oncological patients with an invasive fungal infection is generally poor and the identification of the causative agent is usually not achieved or in some cases the isolated agent is taken as a contaminant and not treated, which contributes to their bad outcome. We report a case of Talaromyces amestolkiae pulmonary infection in an acute lymphoblastic leukemia patient, which was successfully treated with voriconazole, and discuss the importance of molecular identification and treatment of non-traditionally pathogenic fungi in this specific subset of patients.
Copyright © 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immunocompromised; Leukemia; Talaromyces amestolkiae; Voriconazole

Mesh:

Substances:

Year:  2017        PMID: 28161296     DOI: 10.1016/j.jiac.2016.12.017

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  2 in total

1.  Environmental Factors Affecting Diversity, Structure, and Temporal Variation of Airborne Fungal Communities in a Research and Teaching Building of Tianjin University, China.

Authors:  Yixuan Lu; Xiao Wang; Lucineidy C S de S Almeida; Lorenzo Pecoraro
Journal:  J Fungi (Basel)       Date:  2022-04-22

2.  Characterization of Clinical Isolates of Talaromyces marneffei and Related Species, California, USA.

Authors:  Linlin Li; Katelyn Chen; Nirmala Dhungana; Yvonne Jang; Vishnu Chaturvedi; Ed Desmond
Journal:  Emerg Infect Dis       Date:  2019-09       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.